| Drug Name |
Ingenol mebutate |
| Drug ID |
BADD_D01158 |
| Description |
Ingenol mebutate was approved by the FDA in January 2012, and it is marketed under the name Picato®. Picato gel is indicated for the topical treatment of actinic keratosis. Before approval, ingenol mebutate was called PEP005 as an investigational drug. PEP005 is a selective small molecule activator of protein kinase C (PKC) extracted from the plant Euphorbia peplus, whose sap has been used as a traditional medicine for the treatment of skin conditions including warts and cancer. PEP005 also has potent anti-leukemic effects, inducing apoptosis in myeloid leukemia cell lines and primary AML cells at nanomolar concentrations. |
| Indications and Usage |
For the topical treatment of actinic keratosis. |
| Marketing Status |
Prescription |
| ATC Code |
D06BX02 |
| DrugBank ID |
DB05013
|
| KEGG ID |
D09393
|
| MeSH ID |
C486592
|
| PubChem ID |
6918670
|
| TTD Drug ID |
D0E9KA
|
| NDC Product Code |
61200-037; 50222-503; 47848-047 |
| Synonyms |
3-ingenyl angelate | ingenol 3-angelate | 3-ingenol angelate | PEP005 | PEP-005 | PEP 005 | picato | ingenol mebutate |
